For the quarter ending 2025-09-30, SABS has $183,448,368 in assets. $18,374,019 in debts. $29,424,708 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 29,424,708 | 3,692,217 | ||
| Short-term investments | 81,455,925 | 2,021,335 | ||
| Accrued interest receivable | 559,954 | 0 | ||
| Prepaid expenses and other current assets | 1,836,160 | 3,594,569 | ||
| Total current assets | 113,276,747 | 9,308,121 | ||
| Deferred issuance cost | 0 | 261,105 | ||
| Long-term prepaid assets | 124,073 | 156,381 | ||
| Long-term investments | 50,608,587 | - | ||
| Operating lease right-of-use assets | 2,806,904 | 3,006,354 | ||
| Financing lease right-of-use assets | 3,517,718 | 3,539,423 | ||
| Total property, plant and equipment, gross | 29,935,070 | - | ||
| Less accumulated depreciation and amortization | 16,820,731 | - | ||
| Property, plant and equipment, net | 13,114,339 | 13,858,104 | ||
| Total assets | 183,448,368 | 30,129,488 | ||
| Notes payable | 0 | 0 | ||
| Accounts payable | 2,954,985 | 2,622,357 | ||
| Accrued expenses and other current liabilities | 6,850,015 | 7,091,760 | ||
| Operating lease liabilities, current portion | 837,286 | 815,064 | ||
| Finance lease liabilities, current portion | 151,033 | 148,156 | ||
| Total current liabilities | 10,793,319 | 10,677,337 | ||
| Operating lease liabilities, noncurrent | 2,037,461 | 2,255,008 | ||
| Finance lease liabilities, noncurrent | 3,161,562 | 3,200,416 | ||
| Warrant liabilities | 2,381,677 | 1,980,512 | ||
| Total liabilities | 18,374,019 | 18,113,273 | ||
| Preferred stock-Series APreferred Stock | 3 | - | ||
| Preferred stock 0.0001 par value 10,000,000 shares authorized, 42,019 shares issued and outstanding at june 30, 2025 and december 31, 2024, respectively | - | 5 | ||
| Preferred stock-Series BPreferred Stock | 64 | - | ||
| Common stock 0.0001 par value 800,000,000 shares authorized at september 30, 2025 and december 31, 2024 47,548,659 and 9,343,533 shares issued at september 30, 2025 and december 31, 2024, respectively, and 47,493,994 and 9,288,868 outstanding at september 30, 2025 and december 31, 2024, respectively | 4,756 | 936 | ||
| Treasury stock, at cost 54,665 shares held at september 30, 2025 and december 31, 2024, respectively | 5,521,246 | 5,521,246 | ||
| Additional paid-in capital | 264,553,973 | 157,032,218 | ||
| Accumulated other comprehensive income (loss) | 71,223 | -15,805 | ||
| Accumulated deficit | -94,034,424 | -139,479,893 | ||
| Total stockholders' equity | 165,074,349 | 12,016,215 | ||
| Total liabilities and stockholders' equity | 183,448,368 | 30,129,488 | ||
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS)